Clinical trial · Observational
Pancreatic Cancer Biomarker Study
Evaluation of a Biomarker Panel for the Diagnosis and Prognosis of Pancreatic Cancer
NCT04143152CI-TRIAL-00076374unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Diagnostic/prognostic cohort
- description
- Patients being evaluated for a potential pancreatic abnormality or for potential treatment for pancreatic adenocarcinoma.
- label
- Surveillance Cohort
- description
- Patients who are being monitored for recurrence following surgical or medical treatment for pancreatic adenocarcinoma
Primary outcomes (2)
- measure
- Diagnosis of adenocarcinoma of the pancreas
- timeFrame
- Up to three years
- description
- Number of patients clinically diagnosed with pancreatic adenocarcinoma
- measure
- Investigational biomarker panel for diagnosis
- timeFrame
- Enrollment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Diagnosis/Prognosis Cohort * Patients being evaluated for possible pancreatic abnormality, via additional radiological test (endoscopic ultrasound, abdominal CT scan), blood test (CA19-9), or other diagnostic procedure. * Patients being evaluated for medical or surgical treatment for pancreatic cancer or pancreatitis on the basis of previous clinical and radiological findings. Surveillance Cohort * Patients being monitored or who will be monitored for potential recurrence of pancreatic cancer following surgical or medical treatment of pancreatic adenocarcinoma. Exclusion Criteria: * The participant is unwilling or unable to provide written informed consent. * In the investigator's opinion, the participant is unsuitable for the study. * The participant does not speak English. * The participant is a prisoner. * The participant is known to be pregnant. * The participant is less than 18 years of age.
References
Publications (1)
- BACKGROUNDStaal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, Partyka K, Hurd MW, Singhi AD, Drake RR, Huang Y, Maitra A, Brand RE, Haab BB. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis. Clin Cancer Res. 2019 May 1;25(9):2745-2754. doi: 10.1158/1078-0432.CCR-18-3310. Epub 2019 Jan 7. PMID 30617132